Previous studies have also reported that application of PT-2385 could specifically inhibit HIF-2α, to increase androgen receptors, suppress downstream factors such as STAT3, and activate the Akt and ERK signaling pathways, thereby improve sorafenib efficacy in HCC cells both in vivo and in vitro (128). Here, EPAS1 is linked to hepatocellular carcinoma.